Sign in

Private company

Adamas Pharmaceuticals (United States)

Adamas Pharmaceuticals (United States) is an American pharmaceutical preparations company based in Emeryville.1 It was founded in 2002.1

Last updated Oct 21, 2026.

Overview

2002Founded1
  • IndustryPharmaceutical Preparations1
  • HeadquartersEmeryville1
  • Websitewww.adamaspharma.com
  • Incorporated inDE4
  • Business address1900 Powell St., Suite 1000, Emeryville, Ca 946084
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation3
  • LEI529900JBG6S9MXH83I793
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressc/o The Prentice-Hall Corporation, Inc., 251 Little Falls Drive, 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 33055903

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-59.3%Operating margin5
-77.1%Net margin5
36.3%Revenue growth, 20205
-$50.7MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2020

  • Cost of revenue2¢$2.0M
  • Research and development7¢$9.7M
  • Selling, general and admin81¢$106.8M
  • Interest11¢$14.0M

Out of $74.5M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$74.5M in 2020+33% since 2014
0$20.0M$40.0M$60.0M$80.0M2014: $55.8M$55.8M20142015: $1.9M$1.9M2015−97%2016: $572.0K$572.0K2016−70%2017: $571.0K$571.0K2017−0%2018: $34.0M$34.0M2018+5863%2019: $54.6M$54.6M2019+60%2020: $74.5M$74.5M2020+36%
Operating income67895-$44.2M in 2020
-$150.0M-$100.0M-$50.0M0$50.0M2014: $18.5M$18.5M20142015: -$57.4M-$57.4M20152016: -$61.0M-$61.0M2016+6%2017: -$87.9M-$87.9M2017+44%2018: -$115.0M-$115.0M2018+31%2019: -$92.2M-$92.2M2019−20%2020: -$44.2M-$44.2M2020−52%
Net income67895-$57.4M in 2020
-$150.0M-$100.0M-$50.0M0$50.0M2014: $10.2M$10.2M20142015: -$51.8M-$51.8M20152016: -$60.1M-$60.1M2016+16%2017: -$89.5M-$89.5M2017+49%2018: -$131.0M-$131.0M2018+46%2019: -$105.2M-$105.2M2019−20%2020: -$57.4M-$57.4M2020−45%
Fiscal year2014201520162017201820192020
Revenue$55.8M6$1.9M7$572.0K8$571.0K9$34.0M9$54.6M5$74.5M5
Cost of revenue$07$08$17.0K9$633.0K9$2.5M5$2.0M5
Research and development$21.9M6$35.9M7$31.2M8$27.2M9$39.3M9$30.0M5$9.7M5
Selling, general and admin$23.5M7$30.3M8$61.3M9$109.1M9$114.4M5$106.8M5
Operating income$18.5M6-$57.4M7-$61.0M8-$87.9M9-$115.0M9-$92.2M5-$44.2M5
Interest$07$08$4.6M9$19.1M9$15.0M5$14.0M5
Income tax$7.4M6-$5.3M7-$115.0K8-$1.7M9$09$05$05
Net income$10.2M6-$51.8M7-$60.1M8-$89.5M9-$131.0M9-$105.2M5-$57.4M5
Earnings per share$0.606-$2.866-$2.776
Earnings per share (diluted)$0.536-$2.866-$2.776

Compare Adamas Pharmaceuticals (United States) with another company

Corporate structure

Adamas Pharmaceuticals (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Adamas Pharmaceuticals (United States)

  • Adamas Pharmaceuticals (United States) Emeryville, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Adamas Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$5.9M5 Dec 31, 2020$5.9M5 Dec 31, 20190%
Accumulated depreciation$4.3M5 Dec 31, 2020$3.5M5 Dec 31, 2019+24.6%
Property and equipment, net$1.6M5 Dec 31, 2020$2.4M5 Dec 31, 2019−34.7%
Operating-lease assets (leased space)$6.7M5 Dec 31, 2020$8.0M5 Dec 31, 2019−17.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$71.7M5 Dec 31, 2020$65.8M5 Dec 31, 2019+8.9%
Marketable securities, current$11.7M5 Dec 31, 2020$66.8M5 Dec 31, 2019−82.5%
Debt securities available for sale$11.7M5 Dec 31, 2020$66.8M5 Dec 31, 2019−82.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$7.3M5 Dec 31, 2020$5.3M5 Dec 31, 2019+38.5%
Raw materials$795.0K5 Dec 31, 2020$1.1M5 Dec 31, 2019−24.8%
Work in process$4.4M5 Dec 31, 2020$1.9M5 Dec 31, 2019+128.7%
Finished goods$2.1M5 Dec 31, 2020$2.3M5 Dec 31, 2019−8.3%

Leadership

Who has led Adamas Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Gregory T. Went2014–2019
  2. Neil F. McFarlane2019–2021

Chief financial officer

  1. Anthony M. Rimac2014
  2. Alfred G. Merriweather2017–2019
  3. Christopher B. Prentiss2019–2021

Chief operating officer

  1. Jeffrey H. Knapp2015
20052010201520202025
Board members and other officers (22)

Former names

  • NeuroMolecular Pharmaceuticals IncMay 19, 2005 to Jul 17, 20064

Timeline

  1. Nov 24, 20218-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights38
  2. Oct 12, 20218-K Entered a material agreement; Other events39
  3. Sep 17, 2019New chief executive Neil F. McFarlane becomes CEO11
  4. Apr 9, 2014New chief executive Gregory T. Went becomes CEO12
  5. 2002Founded Founded1

Filings

43 filings to the SEC since October 2021: 1 quarterly reports, 2 major events, 10 insider forms, 6 large holders, 24 other. The latest 20:

  1. Feb 15, 2022SC 13G/A EDGAR
  2. Feb 14, 2022SC 13G/A EDGAR
  3. Jan 26, 2022SC 13G/A EDGAR
  4. Dec 10, 2021SC 13G/A EDGAR
  5. Dec 6, 202115-12B EDGAR
  6. Dec 1, 2021EFFECT EDGAR
  7. Nov 24, 202125-NSE EDGAR
  8. Nov 24, 20214 EDGAR
  9. Nov 24, 20214 EDGAR
  10. Nov 24, 20214 EDGAR
  11. Nov 24, 20214 EDGAR
  12. Nov 24, 20214 EDGAR
  13. Nov 24, 20214 EDGAR
  14. Nov 24, 20214 EDGAR
  15. Nov 24, 20214 EDGAR
  16. Nov 24, 20214 EDGAR
  17. Nov 24, 20214 EDGAR
  18. Nov 24, 2021S-8 POS EDGAR
  19. Nov 24, 2021S-8 POS EDGAR
  20. Nov 24, 2021S-8 POS EDGAR

The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Adamas Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAdamas Pharmaceuticals Inc2
  • CIK0001328143
  • Employer ID (EIN)42-15600762
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • Business address1900 Powell St., Suite 1000, Emeryville, CA 946082
  • Phone510-450-35542
  • Shares outstanding45,786,965 as of Oct 31, 202146
  • Public float$60.1M as of Jun 30, 20205
  • On EDGAR sinceMay 19, 20052
  • Filings547 in all: 4 (217), 8-K (84), SC 13G/A (50), 3 (29), 10-Q (24), SC 13G (23), CORRESP (10), 424B5 (9)2
    All 42 form types

    S-8 (9), S-8 POS (9), 10-K (7), DEF 14A (7), UPLOAD (7), DEFA14A (6), EFFECT (5), CT ORDER (4), SC 14D9/A (4), SC14D9C (4), S-1/A (3), S-3 (3), SC 13D/A (3), SC 14D9 (3), 4/A (2), 424B3 (2), REGDEX (2), REGDEX/A (2), SC 13D (2), SC TO-T/A (2), SEC STAFF LETTER (2), 15-12B (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), ARS (1), CERTNAS (1), DRS (1), FWP (1), POS AM (1), S-1 (1), SC TO-C (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2021
    Quarterly report (10-Q) Nov 10, 2021
    Proxy statement (DEF 14A) Apr 19, 2021
    Latest 8-K (8-K) Nov 24, 2021

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46